Western blot analysis for the total and phosphorylated levels of c-Met in BT-474 and MDA-MB-231 cancer cells was considered in order to validate the c-Met inhibitory activity of araguspongine C in breast cancer cell lines. This evidence concerns the gene MET and breast carcinoma.